Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells.
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells / R. Rotolo, V. Leuci, C. Donini, F. Galvagno, A. Massa, M.C. De Santis, S. Peirone, G. Medico, M. Sanlorenzo, I. Vujic, L. Gammaitoni, M. Basiricò, L. Righi, C. Riganti, I.C. Salaroglio, F. Napoli, F. Tabbò, A. Mariniello, E. Vigna, C. Modica, L. D'Ambrosio, G. Grignani, R. Taulli, E. Hirsch, M. Cereda, M. Aglietta, G.V. Scagliotti, S. Novello, P. Bironzo, D. Sangiolo. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - (2022). [Epub ahead of print] [10.1158/1078-0432.CCR-22-0761]
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells
S. Peirone;F. Napoli;C. Modica;M. Cereda;
2022
Abstract
Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
